BHQ and SERCA: Five Questions About the Evidence

2026-10-05

This source-grounded overview examines 2,5-di-tert-butylbenzene-1,4-diol (BHQ) as a pharmacological SERCA perturbant, focusing on what the 2025 mouse study found about hematopoietic stem cell mobilization, how strong that evidence is, and where interpretation should stop. It also distinguishes peer-reviewed findings from supplier-described properties and explains why results from HSC biology, vascular smooth muscle, or general calcium signaling research should not be treated as interchangeable.

TRPV1, TRPA1, and TSLP in Nasal Epithelium

2026-10-05

The reference study links epithelial TRPV1 and TRPA1 activation to TSLP production through calcium-dependent NFAT signaling. Its combined imaging, pharmacological, calcium-chelation, and gene-silencing evidence supports a mechanistic model for upper-airway inflammation while leaving important questions about cell context, pathway specificity, and clinical relevance.

Drug Response Metrics in Cancer In Vitro

2026-10-04

Nystatin (Fungicidin) Workflow Guide

2026-10-02

Nystatin (Fungicidin) supports reproducible Candida inhibition, adhesion, membrane-integrity, and antifungal-comparator assays when solubility and vehicle controls are managed carefully. Its value also extends to mechanistic cell-biology workflows, where the reference study used nystatin as a negative control for cholesterol-dependent entry by Spiroplasma eriocheiris.

H2S Persulfidation and Ferroptosis in NSCLC

2026-10-01

A 2024 Molecular Cell study links hydrogen sulfide signaling to ferroptosis through persulfidation of S-adenosyl homocysteine hydrolase. The findings define a metabolic mechanism connecting reduced homocysteine, cysteine, and glutathione availability with enhanced vulnerability of non-small cell lung cancer cells under cystine-depletion conditions.

Protease Inhibitor Cocktail: EDTA-Free Workflow

2026-10-01

Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic degradation during protein extraction, Western blotting, co-immunoprecipitation, and related assays. Its EDTA-free formulation suits workflows sensitive to divalent-cation chelation, but DMSO and individual inhibitor components should be evaluated before use in specialized enzyme assays or sensitive cell systems.

Wortmannin: PI3K Inhibitor Workflows

2026-09-30

Wortmannin enables rapid, pathway-focused tests of PI3K dependence in cancer research, autophagy, apoptosis, and virus-entry studies. This guide connects dose planning, orthogonal readouts, and the GCRV reference study to practical assay design and troubleshooting.

Fluo-4 AM: Reliable Calcium Assay Workflows

2026-09-30

This scenario-based guide explains how Fluo-4 AM, SKU B8807, supports reproducible intracellular calcium concentration measurement in signaling, cytotoxicity, and pharmacological workflows. It covers assay design, loading optimization, data interpretation, storage, and practical product selection without confusing calcium dynamics with direct viability measurements.

ML133 HCl: A Causal Map for Kir2.1 Research

2026-09-29

ML133 HCl is a selective potassium channel inhibitor that helps separate Kir2.1-dependent signaling from downstream vascular remodeling effects. This article translates published pulmonary vascular findings into practical assay-design, interpretation, and validation decisions.

D-Lin-MC3-DMA: LNP Workflow and QC Guide

2026-09-29

D-Lin-MC3-DMA provides an ionizable cationic liposome component for research workflows involving siRNA and mRNA lipid nanoparticles. This guide covers solvent handling, formulation setup, quality control, and failure analysis, while emphasizing that product-dossier benchmarks should not be treated as a validated protocol for every cargo, species, or administration route.

GKT137831 for Redox and Ferroptosis Research

2026-09-28

GKT137831 is a dual NADPH oxidase Nox1/Nox4 inhibitor for connecting ROS biology with vascular remodeling, fibrosis, and membrane-injury assays. This practical guide outlines concentration selection, hypoxia workflows, ferroptosis-oriented readouts, and troubleshooting strategies without overstating an unproven direct link to TMEM16F.

Amiloride (MK-870): Designing Interpretable Assays

2026-09-28

Amiloride (MK-870) can probe epithelial sodium transport, PC2-associated activity, and uPAR-linked processes—but a response alone does not identify its cause. This guide presents a target-aware assay framework and draws a carefully bounded lesson from clinical trial design in WHIM syndrome.

TSPAN18–STIM1 Signaling in Prostate Bone Metastasis

2026-09-27

Zhou et al. identify TSPAN18 as a regulator that protects STIM1 from TRIM32-mediated ubiquitination, sustaining calcium entry and promoting prostate cancer migration, invasion, and bone metastasis. The findings connect protein stability with calcium signaling and suggest a potential target for further study, while leaving important questions about therapeutic translation unresolved.

How Kinase Inhibitors Accelerate p38α Dephosphorylation

2026-09-26

The reference study shows that selected p38α inhibitors can do more than block kinase activity: by stabilizing an activation-loop conformation, they make a phosphothreonine more accessible to the phosphatase WIP1 and accelerate its removal. Biochemical experiments and X-ray structures support this conformation-directed mechanism, while leaving open how broadly it applies beyond the tested inhibitors and experimental system.

Vemurafenib (PLX4032) for Melanoma Resistance

2026-09-25

Use Vemurafenib as a BRAF-targeted perturbation to measure melanoma cell proliferation inhibition and expose adaptive signaling—not simply as a single end-point viability reagent. Pair dose and time courses with an ARID1A-loss model and orthogonal pathway readouts to distinguish initial MAPK suppression from resistance-associated rewiring.